+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a laboratory-made antibody called ePGT121v1-LS that targets a specific part of the HIV virus. This trial involves generally healthy adults without HIV-1 and aims to assess the safety, side effects, proper dosing, how the body processes the drug, and how well it neutralizes HIV in the blood. The study also explores combinations of ePGT121v1-LS with two other antibodies, VRC07-523LS and PGDM1400LS, to see if they interact when used together. The trial is divided into two parts. Part A includes six groups where participants receive ePGT121v1-LS by intravenous IV infusion at varying doses, alone or combined with the other two antibodies, with treatments given at Week 0 and Week 24 over a total of 48 weeks. Part B has two groups where participants receive subcutaneous SC injections of ePGT121v1-LS alone or combined with the other antibodies at two visits spaced 12 weeks apart, with a total duration of 24 weeks. Participants will have scheduled clinic visits throughout the study periods to monitor safety and side effects, including local and systemic reactions and laboratory tests. Researchers will measure antibody levels in the blood, study how the antibodies behave over time, and evaluate their ability to neutralize HIV. The study also includes HIV testing, counseling, and assessment of participants risk behaviors, lasting up to 48 weeks depending on the group.

Age: 18Years - 55YearsAll GendersPhase 1
11 locations
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are generally healthy. This phase 1 trial aims to assess whether these vaccines can initiate or enhance antibody responses against HIV and how a carefully controlled break in antiretroviral therapy impacts these immune responses. About 42 participants will join the study at multiple sites. Participants will receive different vaccine schedules depending on their group one group will get DV700P-RNA at weeks 0 and 8, then DV701B1.1-RNA at week 16 the other group will get DV700P-RNA at week 0 and DV701B1.1-RNA at week 8. Both vaccines are given as intramuscular injections. The study includes a planned interruption of antiretroviral therapy to closely monitor immune responses during this time. During the study, participants will have regular assessments including monitoring for local and systemic reactions within 14 days after each vaccination, as well as tracking any adverse events throughout the study period of up to 88 weeks. Researchers will measure antibody responses and changes in HIV virus sequences at baseline, after vaccination, and following therapy restart. Blood tests, immune cell analysis, and safety labs will be conducted to evaluate vaccine effects and participant health over time.

Age: 18Years - 60YearsAll GendersPhase 1
16 locations
O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of Hiltonol, a Poly-ICLC-adjuvanted CD40.HIVRI.Env VRIPRO vaccine in adults aged 18 to 60 years who previously participated in the HVTN 706 trial. This Phase 1, open-label, non-randomized clinical trial focuses on preventing HIV infections by studying this vaccine in healthy volunteers without HIV. Participants will receive three subcutaneous injections of the CD40.HIVRI.Env VRIPRO vaccine mixed with Hiltonol at weeks 0, 4, and 24. The study includes those who received either the vaccine or placebo in the previous HVTN 706 trial. Throughout the study, safety and immune responses to the vaccine will be closely monitored. During the trial, participants will be assessed for local and systemic reactions for at least 14 days after each vaccine dose. Safety monitoring will continue for up to one year after vaccination, including tracking serious adverse events and other health changes. Researchers will measure various immune responses, including antibody levels and T-cell activity, to evaluate the vaccines effects. Participants will be followed through all clinic visits and contacted 12 months after the last dose, with the total study duration extending to November 2027.

Age: 18Years - 60YearsAll GendersPhase 1
9 locations
I

Actively Recruiting

Researchers are studying how HIV care can be decentralized in Peru to improve retention in care and viral suppression among people living with HIV. This study focuses on developing and assessing a hub and spoke model where HIV services are shifted from secondary health centers SHCs to primary health clinics PHCs. The study is a Type 2 hybrid implementation trial that uses experimental design to generate evidence on decentralization strategies in an urban setting where HIV care is primarily concentrated in SHCs. The intervention combines the Network for the Improvement of Addiction Treatment NIATx with Project ECHO, a tele-education model, to train and support PHC staff in delivering HIV care. The study applies a step-wedge design with sequential rollout across multiple hubs and spokes, including 4 SHCs and 165 PHCs. Participants experience control periods followed by active NIATxECHO intervention phases and maintenance phases, spanning a total observation period of up to 54 months. Participants include clinicians and leaders at PHCs and SHCs who provide or oversee HIV care. The study collects data on the percentage of people with HIV treated at PHCs, retention in care, and viral suppression over time. Researchers assess how well the intervention is adopted and maintained by PHCs, fidelity to the NIATx and ECHO protocols, and adherence to decentralization guidelines. The study duration extends from April 2024 through July 2028, with ongoing monitoring and evaluation throughout this period.

Age: 18Years +All GendersPhase Not Applicable
2 locations

1-10 of 14

1